Applied BioCode (TPE:6598) Cyclically Adjusted Book per Share: NT$10.02 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6598 Applied BioCode Corp TPE:6598
75 GF Score
Price NT$27.00
GF Value NT$31.95
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Applied BioCode Cyclically Adjusted Book per Share?

Applied BioCode TPE:6598 -0.74% 75 Cyclically Adjusted Book per Share is NT$10.02 as of Jun. 2026. GuruFocus rates TPE:6598 with a GF Score™ of 75/100 and a GF Value™ of NT$31.95 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Applied BioCode's adjusted book value per share for the three months ended in Jun. 2026 was NT$6.823. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$10.02 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-09-05), Applied BioCode's current stock price is NT$27.00. Applied BioCode's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was NT$10.02. Applied BioCode's Cyclically Adjusted PB Ratio of today is 2.69.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Applied BioCode was 3.00. The lowest was 2.13. And the median was 2.42.


Applied BioCode  (TPE:6598) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Applied BioCode's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=27.00/10.02
=2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Applied BioCode was 3.00. The lowest was 2.13. And the median was 2.42.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Applied BioCode Cyclically Adjusted Book per Share Related Terms


Applied BioCode Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Applied BioCode's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Applied BioCode Cyclically Adjusted Book per Share Chart

Applied BioCode Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Applied BioCode Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 10.06 10.02

TPE:6598 vs ABT, SYK, MDT: Cyclically Adjusted Book per Share Comparison

For the Medical Devices subindustry, Applied BioCode's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied BioCode Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Applied BioCode's Cyclically Adjusted PB Ratio falls into.


TPE:6598
75GF Score
Applied BioCode Corp TPE:6598
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Applied BioCode Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Applied BioCode's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.823/333.9520*333.9520
=6.823

Current CPI (Jun. 2026) = 333.9520.

Applied BioCode Quarterly Data

Book Value per Share CPI Adj_Book
201312 6.075 233.049 8.705
201412 11.219 234.812 15.956
201512 0.000 236.525 0.000
201606 10.871 241.018 15.063
201612 8.504 241.432 11.763
201706 5.229 244.955 7.129
201712 5.100 246.524 6.909
201806 2.925 251.989 3.876
201809 0.000 252.439 0.000
201812 6.585 251.233 8.753
201903 0.000 254.202 0.000
201906 4.295 256.143 5.600
201909 7.477 256.759 9.725
201912 6.938 256.974 9.016
202003 6.368 258.115 8.239
202006 12.753 257.797 16.520
202009 12.271 260.280 15.744
202012 12.583 260.474 16.133
202103 12.335 264.877 15.552
202106 11.452 271.696 14.076
202109 10.765 274.310 13.106
202112 10.441 278.802 12.506
202203 9.926 287.504 11.530
202206 9.973 296.311 11.240
202209 10.122 296.808 11.389
202212 9.432 296.797 10.613
202303 8.790 301.836 9.725
202306 8.282 305.109 9.065
202309 8.072 307.789 8.758
202312 7.639 306.746 8.317
202403 7.143 312.332 7.637
202406 6.669 314.175 7.089
202409 8.937 315.301 9.466
202412 8.550 315.605 9.047
202503 8.310 319.799 8.678
202506 6.903 322.561 7.147
202509 6.688 324.800 6.876
202512 6.256 324.054 6.447
202603 6.570 330.213 6.644
202606 6.823 333.952 6.823

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$10.02 mean?
Applied BioCode (TPE:6598) has a Cyclically Adjusted Book per Share of NT$10.02 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Applied BioCode and its competitors.
Is Applied BioCode's Cyclically Adjusted Book per Share too high?
Applied BioCode's current Cyclically Adjusted Book per Share is NT$10.02. Overall, Applied BioCode has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Cyclically Adjusted Book per Share compare to ABT and SYK?
Applied BioCode's Cyclically Adjusted Book per Share of NT$10.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Applied BioCode and its competitors. Applied BioCode's current Cyclically Adjusted Book per Share is NT$10.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$31.95, compared to a current price of NT$27.00 — trading 15.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$10.02. Applied BioCode's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Cyclically Adjusted Book per Share is NT$10.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Applied BioCode (TPE:6598) Overvalued in 2026?

Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued. The current stock price of NT$27.00 is trading 15.5% below its estimated GF Value™ of NT$31.95. GuruFocus considers Applied BioCode to be Modestly Undervalued.

Key valuation signals for TPE:6598:

  • Cyclically Adjusted Book per Share: NT$10.02
  • GF Value™: NT$31.95 vs. price of NT$27.00 (15.5% below fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Applied BioCode Business Description

Address 12130 Mora Dr., Unit 2, Santa Fe Springs, CA, USA, 90670
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
75GF Score

Get the complete analysis for TPE:6598

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.00
Price
NT$31.95
GF Value